The incidence and implications of aldosterone breakthrough (Q36918649)

17 August 2017

1 reference

title

The incidence and implications of aldosterone breakthrough (English)

1 reference

17 August 2017

Andrew S Bomback

1

1 reference

PubMed ID

17717561

17 August 2017

Philip J Klemmer

series ordinal

2

1 reference

17 August 2017

1 September 2007

1 reference

Nature Clinical Practice Nephrology

17 August 2017

1 reference

17 August 2017

3

1 reference

17 August 2017

486-492

1 reference

17 August 2017

9

1 reference

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Antihypertensive Therapy with MK 4211

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

The clinical implications of aldosterone escape in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone and cardiac fibrosis: in vitro studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Role of aldosterone in the remnant kidney model in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone in the development and progression of renal injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone in congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: heartening news for the kidney?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Secondary rise of albuminuria under AT1-receptor blockade--what is the potential role of aldosterone escape?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Control of aldosterone secretion: a model for convergence in cellular signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

The Role of the Glucocorticoid Receptor in Mineralocorticoid/Salt-Mediated Cardiac Fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0575

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0575

1 reference

17 August 2017

1 reference

PubMed ID

17717561